UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000060206
Receipt number R000068861
Scientific Title Factors Associated with Treatment Decision-Making in Cancer Patients Who Place Priority on Quality of Life: A Scoping Review
Date of disclosure of the study information 2025/12/25
Last modified on 2025/12/25 18:05:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Factors Associated with Treatment Decision-Making in Cancer Patients Who Place Priority on Quality of Life: A Scoping Review

Acronym

Factors Associated with Treatment Decision-Making in Cancer Patients Who Place Priority on Quality of Life: A Scoping Review

Scientific Title

Factors Associated with Treatment Decision-Making in Cancer Patients Who Place Priority on Quality of Life: A Scoping Review

Scientific Title:Acronym

Factors Associated with Treatment Decision-Making in Cancer Patients Who Place Priority on Quality of Life: A Scoping Review

Region

Japan


Condition

Condition

patients with unresectable advanced cancer and/or recurrent disease

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To identify factors underlying older cancer patients preference for quality of life over chemotherapy aimed at life prolongation

Basic objectives2

Others

Basic objectives -Others

To clarify the reasons for choosing palliative care over chemotherapy

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Decision-making factors prioritizing quality of life over life-prolonging treatment

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

Population:Patients with cancer
Concept:Factors influencing decision-making that prioritizes quality of life over life-prolonging chemotherapy, including patients' values, symptom burden, family structure, socioeconomic circumstances, and relationships with physicians
Context:Decision-making in cancer treatment settings, regardless of outpatient or inpatient care

Key exclusion criteria

Research using languages other than Japanese or English.
Excluding review articles, commentaries, and conference proceedings.

Target sample size



Research contact person

Name of lead principal investigator

1st name Takenori
Middle name
Last name Ichimura

Organization

Tokyo University of Pharmacy and Life Sciences

Division name

Center for Experimental Pharmacy Practice, School of Pharmacy

Zip code

192-0392

Address

1432-1, Horinouchi, Hachioji, Tokyo, Japan

TEL

042-676-5189

Email

ichimura@toyaku.ac.jp


Public contact

Name of contact person

1st name Takenori
Middle name
Last name Ichimura

Organization

Tokyo University of Pharmacy and Life Sciences

Division name

Center for Experimental Pharmacy Practice, School of Pharmacy

Zip code

192-0392

Address

1432-1, Horinouchi, Hachioji, Tokyo, Japan

TEL

042-676-5189

Homepage URL


Email

ichimura@toyaku.ac.jp


Sponsor or person

Institute

Tokyo University of Pharmacy and Life Sciences

Institute

Department

Personal name



Funding Source

Organization

Tokyo University of Pharmacy and Life Sciences

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo University of Pharmacy and Life Sciences

Address

1432-1, Horinouchi, Hachioji, Tokyo, Japan

Tel

042-676-5189

Email

ichimura@toyaku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

0

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2025 Year 11 Month 17 Day

Date of IRB

2025 Year 11 Month 17 Day

Anticipated trial start date

2025 Year 11 Month 17 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry

2026 Year 03 Month 31 Day

Date trial data considered complete

2026 Year 03 Month 31 Day

Date analysis concluded

2026 Year 05 Month 31 Day


Other

Other related information

For this topic, literature will be searched and extracted using Ichushi-Web, PubMed, and CENTRAL, and the findings will be synthesized to derive implications for future research.


Management information

Registered date

2025 Year 12 Month 25 Day

Last modified on

2025 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068861